QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
OTCMKTS:SMLR

Semler Scientific Competitors

$102.00
-11.00 (-9.73 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$99.40
Now: $102.00
$110.00
50-Day Range
$82.00
MA: $98.10
$117.00
52-Week Range
$30.00
Now: $102.00
$118.97
Volume16,530 shs
Average Volume23,346 shs
Market Capitalization$683.50 million
P/E Ratio71.83
Dividend YieldN/A
Beta1.11

Competitors

Semler Scientific (OTCMKTS:SMLR) Vs. INMD, OM, BLFS, TMDX, NTUS, and AXGN

Should you be buying SMLR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Semler Scientific, including InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), TransMedics Group (TMDX), Natus Medical (NTUS), and AxoGen (AXGN).

Semler Scientific (OTCMKTS:SMLR) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Valuation and Earnings

This table compares Semler Scientific and InMode's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26
InMode$156.36 million13.88$61.15 million$1.6042.44

InMode has higher revenue and earnings than Semler Scientific. InMode is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Semler Scientific and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Semler Scientific32.08%67.38%52.42%
InMode32.57%28.56%24.14%

Institutional and Insider Ownership

12.1% of Semler Scientific shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Semler Scientific has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Semler Scientific and InMode, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Semler Scientific00203.00
InMode00403.00

Semler Scientific currently has a consensus target price of $110.50, indicating a potential upside of 8.33%. InMode has a consensus target price of $71.50, indicating a potential upside of 5.30%. Given Semler Scientific's higher probable upside, analysts plainly believe Semler Scientific is more favorable than InMode.

Summary

Semler Scientific beats InMode on 7 of the 13 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and Semler Scientific (OTCMKTS:SMLR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Outset Medical and Semler Scientific, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
Semler Scientific00203.00

Outset Medical currently has a consensus price target of $55.00, indicating a potential upside of 10.86%. Semler Scientific has a consensus price target of $110.50, indicating a potential upside of 8.33%. Given Outset Medical's higher probable upside, research analysts clearly believe Outset Medical is more favorable than Semler Scientific.

Valuation & Earnings

This table compares Outset Medical and Semler Scientific's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26

Semler Scientific has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and Semler Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
Semler Scientific32.08%67.38%52.42%

Insider and Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 12.1% of Semler Scientific shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Semler Scientific beats Outset Medical on 6 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Institutional & Insider Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 12.1% of Semler Scientific shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by company insiders. Comparatively, 13.6% of Semler Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares BioLife Solutions and Semler Scientific's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million43.39$-1,660,000.00$0.08453.50
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26

Semler Scientific has higher revenue and earnings than BioLife Solutions. Semler Scientific is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioLife Solutions and Semler Scientific, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions02802.80
Semler Scientific00203.00

BioLife Solutions currently has a consensus target price of $32.4444, suggesting a potential downside of 10.57%. Semler Scientific has a consensus target price of $110.50, suggesting a potential upside of 8.33%. Given Semler Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Semler Scientific is more favorable than BioLife Solutions.

Profitability

This table compares BioLife Solutions and Semler Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Semler Scientific32.08%67.38%52.42%

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Summary

Semler Scientific beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.

Semler Scientific (OTCMKTS:SMLR) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Risk & Volatility

Semler Scientific has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Insider & Institutional Ownership

12.1% of Semler Scientific shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Semler Scientific and TransMedics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Semler Scientific32.08%67.38%52.42%
TransMedics Group-131.35%-38.95%-24.10%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Semler Scientific and TransMedics Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Semler Scientific00203.00
TransMedics Group02302.60

Semler Scientific presently has a consensus price target of $110.50, suggesting a potential upside of 8.33%. TransMedics Group has a consensus price target of $36.60, suggesting a potential upside of 14.30%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Semler Scientific.

Earnings & Valuation

This table compares Semler Scientific and TransMedics Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26
TransMedics Group$23.60 million36.85$-33,550,000.00($2.36)-13.57

Semler Scientific has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Semler Scientific beats TransMedics Group on 9 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Risk & Volatility

Natus Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Natus Medical and Semler Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Semler Scientific00203.00

Semler Scientific has a consensus target price of $110.50, indicating a potential upside of 8.33%. Given Semler Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Semler Scientific is more favorable than Natus Medical.

Earnings and Valuation

This table compares Natus Medical and Semler Scientific's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.70$-15,670,000.00$1.2420.02
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26

Semler Scientific has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Natus Medical and Semler Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Semler Scientific32.08%67.38%52.42%

Institutional and Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 12.1% of Semler Scientific shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by insiders. Comparatively, 13.6% of Semler Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Semler Scientific beats Natus Medical on 12 of the 14 factors compared between the two stocks.

Semler Scientific (OTCMKTS:SMLR) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Institutional & Insider Ownership

12.1% of Semler Scientific shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 13.6% of Semler Scientific shares are held by company insiders. Comparatively, 6.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Semler Scientific and AxoGen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Semler Scientific00203.00
AxoGen02302.60

Semler Scientific presently has a consensus price target of $110.50, suggesting a potential upside of 8.33%. AxoGen has a consensus price target of $23.75, suggesting a potential upside of 19.17%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Semler Scientific.

Profitability

This table compares Semler Scientific and AxoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Semler Scientific32.08%67.38%52.42%
AxoGen-22.98%-19.83%-14.88%

Risk and Volatility

Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Semler Scientific and AxoGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Semler Scientific$32.77 million20.86$15.08 million$1.8854.26
AxoGen$106.71 million7.61$-29,140,000.00($0.68)-29.31

Semler Scientific has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Semler Scientific beats AxoGen on 10 of the 14 factors compared between the two stocks.


Semler Scientific Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
InMode logo
INMD
InMode
1.5$67.90-11.2%$2.17 billion$156.36 million48.85High Trading Volume
News Coverage
Outset Medical logo
OM
Outset Medical
0.9$49.61-1.8%$2.12 billionN/A0.00Upcoming Earnings
BioLife Solutions logo
BLFS
BioLife Solutions
1.5$36.28-4.3%$1.19 billion$27.37 million-49.70Upcoming Earnings
TransMedics Group logo
TMDX
TransMedics Group
1.4$32.02-17.0%$869.70 million$23.60 million-22.87Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
NTUS
Natus Medical
1.1$24.83-3.9%$841.09 million$495.52 million-45.15Earnings Announcement
Analyst Upgrade
AxoGen logo
AXGN
AxoGen
1.5$19.93-8.4%$811.89 million$106.71 million-31.63Analyst Report
High Trading Volume
ViewRay logo
VRAY
ViewRay
1.3$4.15-2.4%$616.28 million$87.78 million-4.66News Coverage
Gap Up
Zynex logo
ZYXI
Zynex
1.7$14.54-2.0%$525.40 million$45.47 million44.06Earnings Announcement
High Trading Volume
Analyst Revision
Stereotaxis logo
STXS
Stereotaxis
0.6$6.91-7.8%$509.17 million$28.90 million-62.82Earnings Announcement
Analyst Downgrade
Cutera logo
CUTR
Cutera
1.5$26.02-33.2%$458.81 million$181.71 million-14.38High Trading Volume
Gap Up
Edap Tms logo
EDAP
Edap Tms
1.3$7.32-9.8%$213.32 million$50.23 million-122.00Increase in Short Interest
News Coverage
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$2.63-0.8%$209.39 millionN/A-3.46Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
1.2$4.19-3.6%$128.71 millionN/A0.00News Coverage
Gap Down
FONR
FONAR
1.1$19.29-2.3%$126.43 million$85.69 million18.20
Electromed logo
ELMD
Electromed
1.8$12.11-2.8%$104.57 million$32.47 million28.83News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.22-3.5%$100.34 million$43.45 million-13.13Upcoming Earnings
Analyst Report
Decrease in Short Interest
electroCore logo
ECOR
electroCore
1.2$1.96-14.8%$89.09 million$2.39 million-2.48Gap Down
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.13-15.5%$80.06 million$10,000.00-1.16Decrease in Short Interest
News Coverage
Gap Up
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
Second Sight Medical Products logo
EYES
Second Sight Medical Products
1.5$1.43-21.7%$33.06 million$3.38 million-0.75Decrease in Short Interest
News Coverage
Gap Up
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
1.0$5.20-5.8%$32.07 million$15.09 million0.00Increase in Short Interest
News Coverage
Gap Up
HSDT
Helius Medical Technologies
1.0$12.68-7.3%$29.30 million$1.50 million-0.73Upcoming Earnings
Decrease in Short Interest
News Coverage
PEYE
Precision Optics
0.4$1.52-0.0%$20.16 million$9.92 million-15.20
CHF Solutions logo
CHFS
CHF Solutions
1.7$6.93-15.9%$18.96 million$5.51 million-0.14Earnings Announcement
Increase in Short Interest
News Coverage
Gap Up
VASO
Vaso
0.9$0.09-11.1%$16.67 million$75.75 million4.50News Coverage
Gap Up
Digirad logo
DRAD
Digirad
1.4$2.79-8.2%$13.28 million$114.18 million-0.89Upcoming Earnings
Gap Down
STRR
Star Equity
0.1$2.79-8.2%$13.28 million$114.18 million-0.89Upcoming Earnings
News Coverage
Gap Down
GTHP
Guided Therapeutics
0.3$0.85-0.0%$11.20 million$40,000.00-3.54Decrease in Short Interest
News Coverage
Gap Down
MICR
Micron Solutions
0.3$3.18-5.7%$10.69 million$17.50 million22.72Decrease in Short Interest
Gap Down
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.02-7.6%$6.54 million$6.57 million-0.01Increase in Short Interest
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-0.0%$2.21 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.40-7.1%$1.65 millionN/A7.78
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.04-24.4%$456,000.00N/A0.00Decrease in Short Interest
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.20-0.0%$407,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$265,000.00N/A0.00Gap Down
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$260,000.00N/A0.00Gap Up
ULGX
Urologix
0.6$0.01-0.0%$160,000.00N/A0.00
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
ESMC
Escalon Medical
0.5$0.24-8.5%$0.00$9.40 million-3.92Upcoming Earnings
Gap Up
HRTT
Heart Tronics
0.0$0.02-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-0.0%$0.00N/A0.00Gap Down
PECN
Photoelectron
0.2$0.01-0.0%$0.00N/A0.00Gap Up
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00News Coverage
XCRP
Xcorporeal
0.0$0.01-0.0%$0.00N/A0.00
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.